gatifloxacin has been researched along with Corneal Opacity in 1 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Corneal Opacity: Disorder occurring in the central or peripheral area of the cornea. The usual degree of transparency becomes relatively opaque.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burka, JM | 1 |
| Bower, KS | 1 |
| VanRoekel, RC | 1 |
| Stutzman, RD | 1 |
| Kuzmowych, CR | 1 |
1 trial available for gatifloxacin and Corneal Opacity
| Article | Year |
|---|---|
The effect of moxifloxacin and gatifloxacin on long-term visual outcomes following photorefractive keratectomy.
Topics: Anti-Infective Agents; Aza Compounds; Corneal Opacity; Double-Blind Method; Fluoroquinolones; Follow | 2007 |